February 23, 2018 / 7:03 PM / 10 months ago

BRIEF-Kempharm Announces FDA Approval Of Apadaz

Feb 23 (Reuters) - Kempharm Inc:

* KEMPHARM SAYS U.S. FDA APPROVED NDA FOR APADAZ FOR SHORT-TERM MANAGEMENT OF ACUTE PAIN SEVERE ENOUGH TO REQUIRE OPIOID ANALGESIC

* KEMPHARM SAYS U.S. DRUG ENFORCEMENT ADMINISTRATION INDICATED INTENT TO SCHEDULE APADAZ AS A C-II PRODUCT

* KEMPHARM ANNOUNCES FDA APPROVAL OF APADAZ (BENZHYDROCODONE AND ACETAMINOPHEN) FOR SHORT-TERM MANAGEMENT OF ACUTE PAIN Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below